Intellectia LogoIntellectia
Stock
Crypto
Features
Resources
Company
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo
StockCrypto

Features

AI Stock Picker
Financial AI Agent
Swing Trading
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
Stock Chart Patterns
Earnings Trading
AI Screener

Resources

Resources

Blog
Earnings
Tutorial
Partner Program

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Company

Contact
About
News Release
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. TSHA
    4. >
  4. Forecast

Stock Price Prediction

-
stocks logo
TSHA
-
$
0.000
0.000(0.000%)
    OverviewForecastTechnicalOptionsEarningsFinancialsValuationInsiders

TSHA Similar Chart Price Prediction

The price of TSHA is predicted to go up -5.9%, based on the high correlation periods with ANIK. The similarity of these two price pattern on the periods is 92.4%.

stocks logo

TSHA

stocks logo

ANIK

Down: -5.9%Similarity: 92.4%

TSHA Revenue Forecast

TSHA EPS Forecast

TSHA FAQs

What is bull’s view on TSHA?

TSHA stock has a bullish outlook with analysts maintaining strong buy ratings and price targets ranging from $5 to $8, representing significant upside potential from its current price of $2.53. The optimism is driven by Taysha Gene Therapies' safer intrathecal injection method and promising advancements in its Rett Syndrome trials. Recent analyst updates and a robust product portfolio further reinforce confidence in the stock's growth trajectory.

What is bear's view on TSHA?

TSHA stock is currently bearish, trading at $1.97, down 10.8% in pre-market trading following weak Q3 results. Analysts maintain a positive long-term outlook with price targets of $5-$8, citing safer administration methods and promising gene therapy trials. However, near-term sentiment remains negative due to financial underperformance and market volatility.

What is TSHA revenue forecast for next quarter？

The market consensus for TSHA's revenue in the upcoming quarter is projected to be approximately $1.492M USD.

TSHA VS S&P500

Ask Intellectia about TSHA

TSHA Analyst's Forecast

Whitney Ijem

Canaccord Genuity

Strong Buy

2024-11-15

Price Target

$6 → $8

Upside

+288.35%

Canaccord raised the firm's price target on Taysha Gene Therapies to $8 from $6 and keeps a Buy rating on the shares. The firm said its thinking on the competitive dynamic for Rhett Syndrome has not changed following its Q4 report and they updated its model and target.
Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Product
AI Stock PickerFinancial AI AgentSwing TradingStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisStock Chart PatternsEarnings TradingAI Screener
Support
BlogEarningsTerms of UsePrivacy PolicySitemapPartner Program
Start for Free

Hot Stocks

stocks logo

NFE

New Fortress Energy Inc

$10.5
-3.67%
stocks logo

RDNT

RadNet Inc

$59.67
-0.81%
stocks logo

AB

AllianceBernstein Holding LP

$37.66
0.19%
stocks logo

GBTG

Global Business Travel Group Inc

$8.53
-0.23%
stocks logo

EEFT

Euronet Worldwide Inc

$102.84
1.01%
stocks logo

AHR

American Healthcare REIT Inc

$28.87
4.04%
stocks logo

VCTR

Victory Capital Holdings Inc

$63.14
-1.17%
stocks logo

CBZ

CBIZ Inc

$85.32
1.55%
stocks logo

OMAB

Grupo Aeroportuario del Centro Norte SAB de CV

$76.72
-3.13%
stocks logo

SLAB

Silicon Laboratories Inc

$144.29
-4.72%